TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36906440

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg) in the posaconazole-HSCT population
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab (10 mg/kg) in the fidaxomicin-HSCT population
Number of subjects: 87

Group type: COMPARATOR
Intervention: Pooled Phase III/Phase I data set
Number of subjects: 87
Study: 36906589

Group type: EXPERIMENTAL
Intervention: Families Talking Together Plus (FTT+) intervention (n=375)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Passive control condition (n=375)
Number of subjects: 750
Study: 36906660

Group type: EXPERIMENTAL
Intervention: Rituximab plus belimumab
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rituximab plus placebo
Number of subjects: 36
Study: 36906664

Group type: EXPERIMENTAL
Intervention: CD46-targeted alpha therapy based on YS5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microtubule inhibitor-based antibody drug conjugate
Number of subjects: 0
Study: 36906804

Group type: EXPERIMENTAL
Intervention: Restrictive oxygen strategy
Number of subjects: 1420

Group type: COMPARATOR
Intervention: Liberal oxygen strategy
Number of subjects: 1420
Study: 36906875

Group type: EXPERIMENTAL
Intervention: Intravenous CYT107 (10 µg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous CYT107
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intramuscular CYT107 (previous study)
Number of subjects: 21
Study: 36907376

Group type: EXPERIMENTAL
Intervention: Polysomnography cluster of periodic limb movements of sleep (PLMS)
Number of subjects: 29907

Group type: EXPERIMENTAL
Intervention: Polysomnography cluster of severe desaturations
Number of subjects: 29907

Group type: COMPARATOR
Intervention: Mild polysomnography cluster
Number of subjects: 29907

Group type: COMPARATOR
Intervention: Other polysomnography clusters (poor sleep, severe OSA or sleep fragmentation)
Number of subjects: 29907
Study: 36907457

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Anhedonia (BATA)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 87
Study: 36907736

Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Lower education
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 273
Study: 36907833

Group type: EXPERIMENTAL
Intervention: mHealth pure-tone screening with tympanometry
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: High-frequency mHealth pure-tone screening with tympanometry
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: DPOAE with tympanometry
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: mHealth pure-tone screening with 6 kHz
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: DPOAE plus tympanometry for children 3 to 6 years
Number of subjects: 1449

Group type: EXPERIMENTAL
Intervention: High-frequency mHealth pure-tone screening for children 7 years and older
Number of subjects: 1449
Study: 36907851

Group type: EXPERIMENTAL
Intervention: Standard antibiotic treatment
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vaginal microbiota at birth
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Neonatal meconium communities
Number of subjects: 78
Study: 36907899

Group type: EXPERIMENTAL
Intervention: Breast Cancer Risk Reduction Program (BrCaRRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36907945

Group type: EXPERIMENTAL
Intervention: M-DEPTH depression care model (including antidepressants and individual Problem Solving Therapy)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 391
Study: 36907947

Group type: EXPERIMENTAL
Intervention: Alofanib (350 mg/m2, administered daily intravenously 5 days on, 2 days off)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alofanib
Number of subjects: 21
Study: 36907985

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) initiated within 48 hours post-AIS
Number of subjects: 509
Study: 36907997

Group type: EXPERIMENTAL
Intervention: Antenatal azithromycin (500 mg oral tablets)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no azithromycin)
Number of subjects: 50
Study: 36908150

Group type: COMPARATOR
Intervention: 2 mg pitavastatin
Number of subjects: 293

Group type: COMPARATOR
Intervention: 4 mg pitavastatin
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: 2 mg pitavastatin/10 mg ezetimibe (K-924 LD)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: 4 mg pitavastatin/10 mg ezetimibe (K-924 HD)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Pitavastatin/ezetimibe fixed-dose combination
Number of subjects: 293

Group type: COMPARATOR
Intervention: Pitavastatin monotherapy
Number of subjects: 293

Group type: COMPARATOR
Intervention: Pitavastatin/ezetimibe fixed-dose combination and pitavastatin monotherapy
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 293
Study: 36908163

Group type: EXPERIMENTAL
Intervention: Prior-CB (Cryoablation)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Prior-RF (Radiofrequency catheter ablation)
Number of subjects: 74
Study: 36908314

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg per day
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 36908422

Group type: EXPERIMENTAL
Intervention: DVD/IVR
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Class/IVR
Number of subjects: 334

Group type: COMPARATOR
Intervention: SC
Number of subjects: 334
Study: 36908462

Group type: EXPERIMENTAL
Intervention: Changes to routine activities due to anti-Asian racism
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Changes to routine activities
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Fear for safety due to anti-Asian racism
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Fear for safety
Number of subjects: 175
Study: 36908503

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Daclatasvir
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Daclatasvir
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 36908609

Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MS-ON group, AQP4-IgG+ON group, MOG-IgG+ON group
Number of subjects: 0
Study: 36908614

Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration
Number of subjects: 211

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 211
Study: 36908619

Group type: EXPERIMENTAL
Intervention: ApTOLL (Toll-like receptor 4 antagonist) administered together with endovascular treatment (EVT)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo administered together with endovascular treatment (EVT)
Number of subjects: 151
Study: 36908633

Group type: EXPERIMENTAL
Intervention: Therapeutic Chinese foot massages (TCFM)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 36908662

Group type: EXPERIMENTAL
Intervention: Impaired coronary flow reserve (CFR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflammation
Number of subjects: 0
Study: 36908766

Group type: EXPERIMENTAL
Intervention: Pain, depression, and anxiety medications
Number of subjects: 3246

Group type: COMPARATOR
Intervention: Population controls
Number of subjects: 3246
Study: 36908924

Group type: EXPERIMENTAL
Intervention: Vitamin K2
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 36909004

Group type: EXPERIMENTAL
Intervention: Kinesio tape
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham tape
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study: 36909343

Group type: EXPERIMENTAL
Intervention: Prebiotic supplement
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo shake
Number of subjects: 6
Study: 36909590

Group type: EXPERIMENTAL
Intervention: CommunityRx-Hunger
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: CommunityRx-Dementia
Number of subjects: 640
Study: 36909596

Group type: EXPERIMENTAL
Intervention: Trust-based Relational Intervention (TBRI) Caregiver Training, a trauma-informed intervention program.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trust-based Relational Intervention (TBRI) Caregiver Training
Number of subjects: 0
Study: 36909731

Group type: EXPERIMENTAL
Intervention: Plitidepsin
Number of subjects: 34
Study: 36909845

Group type: EXPERIMENTAL
Intervention: Real-time PCR
Number of subjects: 878

Group type: COMPARATOR
Intervention: Culture-based methods
Number of subjects: 878
Study: 36909848

Group type: EXPERIMENTAL
Intervention: CV Wizard system
Number of subjects: 17931
Study: 36909865

Group type: EXPERIMENTAL
Intervention: HIFEM+RF procedure (four, 30-minute bilateral procedures over the upper arms spaced one week apart)
Number of subjects: 34
Study: 36910109

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 90
Study: 36910250

Group type: EXPERIMENTAL
Intervention: Pre-sleep audio or visual alpha entrainment for 30 minutes each night for 4 weeks
Number of subjects: 28
Study: 36910457

Group type: EXPERIMENTAL
Intervention: Urinary L-type fatty acid-binding protein (L-FABP) measured within 48 hours of admission
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: L-FABP point of care (POC) test
Number of subjects: 224
Study: 36910479

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 36910501

Group type: EXPERIMENTAL
Intervention: Active acupuncture (three times weekly for 14 weeks) added to donepezil treatment (5 mg per day for 28 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture (three times weekly for 14 weeks) added to donepezil treatment (5 mg per day for 28 weeks)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture
Number of subjects: 160
Study: 36910518

Group type: EXPERIMENTAL
Intervention: OCT-guided percutaneous coronary intervention (PCI) with 3-month follow-up OCT imaging (O3 group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Early discontinuation of dual antiplatelet therapy (DAPT)
Number of subjects: 60
Study: 36910537

Group type: EXPERIMENTAL
Intervention: Cardiac shock-wave therapy (CSWT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 72
Study: 36910599

Group type: EXPERIMENTAL
Intervention: Radiomics-based risk score
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram incorporating radiomics data, clinical data, and TNM information
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram
Number of subjects: 78
Study: 36910668

Group type: EXPERIMENTAL
Intervention: Targeted therapy based on molecular profiles
Number of subjects: 27
Study: 36910693

Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) once daily for 48 weeks
Number of subjects: 43
Study: 36911033

Group type: EXPERIMENTAL
Intervention: Prone locomotor training using a robotic crawl training device from 5 to 9 months of age
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Upright locomotor training using a dynamic weight support system from 9 to 18 months of age
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Early spontaneous leg movements measured monthly from 1 to 4 months of age using inertial sensors
Number of subjects: 60
Study: 36911725

Group type: EXPERIMENTAL
Intervention: ARG1- and PD-L1-derived peptide vaccination with Montanide ISA-51 as adjuvant
Number of subjects: 9
Study: 36911944

Group type: EXPERIMENTAL
Intervention: Intrathecal onasemnogene abeparvovec (medium dose)
Number of subjects: 32
Study: 36911951

Group type: EXPERIMENTAL
Intervention: Contextual sensory integration training in virtual reality
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Traditional vestibular rehabilitation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controls (no intervention)
Number of subjects: 30
Study: 36912033

Group type: EXPERIMENTAL
Intervention: Total aortic arch replacement
Number of subjects: 3902

Group type: EXPERIMENTAL
Intervention: Aortic root replacement
Number of subjects: 3902

Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 3902
Study: 36912078

Group type: EXPERIMENTAL
Intervention: Tivozanib plus durvalumab
Number of subjects: 0
Study: 36912144

Group type: EXPERIMENTAL
Intervention: tDCS (1 mA for 20 minutes) plus fifteen 45-minute sessions of naming treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham-tDCS plus fifteen 45-minute sessions of naming treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 58
Study: 36912172

Group type: EXPERIMENTAL
Intervention: Bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Baseline regimens
Number of subjects: 136
Study: 36912439

Group type: EXPERIMENTAL
Intervention: Immediate operation (IOP)
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Delayed operation after active surveillance (DOP)
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Delayed operation after active surveillance (DOP) with disease progression
Number of subjects: 1177
Study: 36912445

Group type: EXPERIMENTAL
Intervention: Customized low-calorie diet with calorie intake equalling their basal requirement along with exercise for 2 weeks before surgery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normal routine lifestyle
Number of subjects: 62
Study: 36912484

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Baricitinib 2 mg
Number of subjects: 168
Study: 36912538

Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Prostatectomy
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 1643
Study: 36912566

Group type: EXPERIMENTAL
Intervention: Isolated CABG with DuraGraft intraoperatively for conduit preservation
Number of subjects: 2532
Study: 36912568

Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreaticoduodenectomy (LPD)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Dilated pancreatic duct (>3 mm)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Advanced age (≥75 years)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Concomitant cardiovascular disease
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Hospital volume, surgeon's experience with open pancreaticoduodenectomy and minimally invasive surgery, surpassing the LPD learning curve
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Different hospitals
Number of subjects: 1029
Study: 36912740

Group type: EXPERIMENTAL
Intervention: Ex-PRESS plus trabeculectomy
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: PreserFlo MicroShunt
Number of subjects: 961

Group type: COMPARATOR
Intervention: Device-modified trabeculectomy
Number of subjects: 961
Study: 36912792

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antivascular endothelial growth factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steroid injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New intravitreal drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive (sometimes surgical) approach
Number of subjects: 0
Study: 36912809

Group type: EXPERIMENTAL
Intervention: Immunotherapy or chemo-immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36912897

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36913051

Group type: EXPERIMENTAL
Intervention: MEN1611
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MEN1611 + trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: taselisib
Number of subjects: 0

Group type: COMPARATOR
Intervention: alpelisib
Number of subjects: 0
Study: 36913378

Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standardized self-compassionate mental imagery instructions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham mental imagery instructions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Heart rate variability
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Eye-tracking task
Number of subjects: 120
Study: 36913433

Group type: EXPERIMENTAL
Intervention: Modified CL Detect Rapid Test (increased extraction time and sample volume)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 156

Group type: COMPARATOR
Intervention: kDNA-PCR
Number of subjects: 156
Study: 36913444

Group type: EXPERIMENTAL
Intervention: Monosaccharide intake
Number of subjects: 0
Study: 36913446

Group type: EXPERIMENTAL
Intervention: 85%-HAF bread
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 70%-HAF bread
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 20
Study: 36913449

Group type: EXPERIMENTAL
Intervention: Egg introduction during infancy
Number of subjects: 1089
Study: 36913483

Group type: EXPERIMENTAL
Intervention: Fruitflow (water-soluble tomato extract)
Number of subjects: 22
Study: 36913518

Group type: EXPERIMENTAL
Intervention: Stimulant medication intake
Number of subjects: 0
Study: 36913642

Group type: EXPERIMENTAL
Intervention: Retroperitoneal lymph node dissection (RPLND)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: RPLND
Number of subjects: 55
Study: 36913694

Group type: EXPERIMENTAL
Intervention: Concurrent pembrolizumab with AVD (doxorubicin, vinblastine, and dacarbazine)
Number of subjects: 30
Study: 36913717

Group type: EXPERIMENTAL
Intervention: Hydrolyzed infant formula
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Fruits and juices
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Vegetables
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Oats
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Potatoes
Number of subjects: 73
Study: 36913959

Group type: COMPARATOR
Intervention: Monthly IPTp with sulfadoxine-pyrimethamine (500 mg of sulfadoxine and 25 mg of pyrimethamine for 1 day)
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Monthly IPTp with dihydroartemisinin-piperaquine (dosed by weight; three to five tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine once daily for 3 consecutive days)
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Monthly IPTp with dihydroartemisinin-piperaquine plus azithromycin (two tablets containing 500 mg once daily for 2 consecutive days)
Number of subjects: 4680
Study: 36914049

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Early cord clamping (ECC)
Number of subjects: 227
Study: 36914185

Group type: EXPERIMENTAL
Intervention: COPDPredict with rescue medication (RM)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Standard self-management plans with rescue medication (RM)
Number of subjects: 384
Study: 36914193

Group type: EXPERIMENTAL
Intervention: Neoadjuvant arterial embolisation chemotherapy (NAEC) with oxaliplatin 85 mg/m²
Number of subjects: 0
Study: 36914233

Group type: EXPERIMENTAL
Intervention: Higher transcutaneous carbon dioxide targeting 5 mm Hg (0.67 kPa) changes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lower transcutaneous carbon dioxide targeting 5 mm Hg (0.67 kPa) changes
Number of subjects: 25
Study: 36914591

Group type: EXPERIMENTAL
Intervention: Dexfadrostat phosphate (DP13) 4 mg once daily for 8 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dexfadrostat phosphate (DP13) 8 mg once daily for 8 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dexfadrostat phosphate (DP13) 16 mg once daily for 8 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 36914652

Group type: EXPERIMENTAL
Intervention: Trotabresib (RP2D of 45 mg/day 4 days on/24 days off or 30 mg/day 3 days on/11 days off)
Number of subjects: 135
Study: 36914809

Group type: EXPERIMENTAL
Intervention: Isolated abnormal FEF75% detected in 26 CF children at age 7.5 ± 4 years, remained an isolated abnormality for 2.5 ± 1.5 years.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Isolated abnormal FEF75% detected in 13 children at age 11.7 ± 4.5 years, and abnormal FEF25-75% in 10 children at age 11.8 ± 5.3 years.
Number of subjects: 39
Study: 36914828

Group type: COMPARATOR
Intervention: GB1211 5, 20, 50, 100, 200, or 400 mg (single ascending-dose)
Number of subjects: 78

Group type: COMPARATOR
Intervention: GB1211 50 or 100 mg (multiple ascending-dose, twice daily for 10 days)
Number of subjects: 78

Group type: COMPARATOR
Intervention: GB1211 (fasted state)
Number of subjects: 78

Group type: COMPARATOR
Intervention: GB1211 (fed state)
Number of subjects: 78
Study: 36914946

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin in addition to standard treatment
Number of subjects: 351

Group type: COMPARATOR
Intervention: Standard treatment only (control group)
Number of subjects: 351
Study: 36914957

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation
Number of subjects: 898

Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Aspirin group
Number of subjects: 898

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 898
Study: 36915009

Group type: EXPERIMENTAL
Intervention: Cytokine profiles measured using a 15-plex human cytokine magnetic bead assay system.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cytokine profiles including IL-6, IL-10, IL-15, MDC, GRO, sCD40 L, G-CSF, and FGF-2.
Number of subjects: 40
Study: 36915062

Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide
Number of subjects: 330

Group type: COMPARATOR
Intervention: Macrogol/electrolytes
Number of subjects: 330